A commercially available test, ConfirmMDx, which measures CpG island methylation of GSTP1, RASSF1, and APC in histopathologically negative prostate core biopsies, has been used clinically to predict PCa and high-grade PCa in repeat biopsies [10,11,12]. This evidence concerns the gene APC and posterior cortical atrophy.